Disease · MONDO_0043905

pneumonitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pneumonitis. Diseases, record MONDO_0043905. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043905

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pneumonitis; Open Targets
Open Targets ID: MONDO_0043905; Open Targets
Other names: Inflammation of the lung parenchyma, Inflammation of the lungs, inflammation of lung parenchyma, lung parenchyma inflammation; Open Targets
NCI Thesaurus: C113159; NCI Thesaurus
Highest stage of its drugs: Phase 2/3, for 1 of its 23 drugs, from ClinicalTrials.gov; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PIRFENIDONE	CHEMBL1256391	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
TOCILIZUMAB	CHEMBL1237022	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LOVASTATIN	CHEMBL503	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
AMIFOSTINE	CHEMBL1006	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets27

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 1	https://conductscience.org/library/genes/2908	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	1	Granulocyte colony stimulating factor receptor agonist	Phase 1/2	https://conductscience.org/library/genes/1441	Drugs and targets
CXCR2	C-X-C chemokine receptor type 2	1	Interleukin-8 receptor B antagonist	Phase 1	https://conductscience.org/library/genes/3579	Drugs and targets
F5	Coagulation factor V	1	Coagulation factor V inhibitor	Unknown	https://conductscience.org/library/genes/2153	Drugs and targets
F8	Coagulation factor VIII	1	Coagulation factor VIII inhibitor	Unknown	https://conductscience.org/library/genes/2157	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Phase 2	https://conductscience.org/library/genes/3156	Drugs and targets
IL6R	Interleukin-6 receptor subunit alpha	1	Interleukin-6 receptor alpha subunit inhibitor	Phase 2	https://conductscience.org/library/genes/3570	Drugs and targets
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TNF	Tumor necrosis factor	1	TNF-alpha inhibitor	Phase 2	https://conductscience.org/library/genes/7124	Drugs and targets
TOP1	DNA topoisomerase 1	1	DNA topoisomerase I inhibitor	Phase 1/2	https://conductscience.org/library/genes/7150	Drugs and targets

1 to 10 of 27

See all 27 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02434081	NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma	Phase 2	94	2021-10-25	Non-small Cell Lung Cancer Stage III	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT01253980	Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children	Not applicable	74	2013-06-26	Kerosene Pneumonitis	AMOXICILLIN	Its record names the disease	ClinicalTrials.gov
NCT04331795	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis	Phase 2	32	2022-06-09	COVID-19	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	Phase 2	1	2021-06-04	Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04438382	Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis	Phase 2	1	2024-03-26	Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT07388680	Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia	Phase 2/3	298		Radiation-induced Lung Injury, Immune-related Pneumonia	PIRFENIDONE	Its record names the disease	ClinicalTrials.gov
NCT00190229	Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura	Not applicable	200		Henoch-Schoenlein Purpura	CYCLOPHOSPHAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00006012	Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer	Phase 1/2	73		Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity	AMIFOSTINE, CISPLATIN, ETOPOSIDE, FILGRASTIM, PACLITAXEL, TOPOTECAN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00943267	Effect of Intrapulmonary Recombinant Human Activated Protein C (APC) on Coagulation and Inflammation After Lipopolysaccharide (LPS)	Not applicable	52		Pneumonia, Lipopolysaccharides	DROTRECOGIN ALFA (ACTIVATED)	Open Targets' reading of its record	ClinicalTrials.gov
NCT05280873	Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP	Phase 1	48		Pneumonitis, Malignant Tumor	METHYLPREDNISOLONE, PIRFENIDONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Amoxicillin vs Placebo: Treatment Failure	2 of 39	3 of 35	74	NCT01253980	Trial comparisons
Amoxicillin vs Placebo: serious adverse events	0 of 39	0 of 35	74	NCT01253980	Trial comparisons
Group A vs Group B: Overall Survival	10 of 12	17 of 20	32	NCT04331795	Trial comparisons
Group A vs Group B: Rate of Non-elective Mechanical Ventilation	2 of 12	4 of 20	32	NCT04331795	Trial comparisons
Group A vs Group B: Survival to Hospital Discharge	1 of 12	2 of 20	32	NCT04331795	Trial comparisons
Group A vs Group B: deaths from any cause	2 of 12	3 of 20	32	NCT04331795	Trial comparisons
Group A vs Group B: Number of Participants With Clinical Response in Maximum Temperature (Tmax)	8 of 12	16 of 20	32	NCT04331795	Trial comparisons
Group A vs Group B: serious adverse events	0 of 12	0 of 20	32	NCT04331795	Trial comparisons
Group A vs Group B: Number of Participants With Biochemical Response as Determined by CRP Response	10 of 11	15 of 18	29	NCT04331795	Trial comparisons

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33210302	RESULT	1	PubMed
26114347	RESULT	1	PubMed
17336213	RESULT	1	PubMed
11961015	RESULT	1	PubMed
36853224	DERIVED	1	PubMed
35868533	DERIVED	1	PubMed
33568350	DERIVED	1	PubMed
23060625	DERIVED	1	PubMed
20505654	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0043905

GET https://conductscience.org/api/diseases/v1/MONDO_0043905/drugs?page=2

API reference For AI assistants